SORT BY:

All Company News

BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor

November 21, 2023

Adcentrx Therapeutics Announces First Patient Dosed in the Phase 1a/b Study of ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

September 27, 2023

Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

July 17, 2023

ENSEM Announces the Promotion of Shengfang Jin, PhD to President & Chief Executive Officer

June 5, 2023

Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures

April 24, 2023

ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets

April 6, 2022

Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates

February 14, 2022

Adcentrx Therapeutics Announces Completion of $50M Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development

April 28, 2021